Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

S Chan, S Chan

Abstract

mTOR is a downstream mediator in the PI3K/Akt signalling pathway, which plays a critical role in regulating basic cellular functions. These include cell proliferation, survival, mobility and angiogenesis. Rapamycin and its analogues (CCI-779, RAD001 and AP23573) have specific antagonistic action on the function of mTOR. This leads to inhibition of the downstream signalling elements and results in the cell cycle arrest in the G1 phase. This group of drugs may have a place in Oncology for the treatment of cancers, which occur as a result of increased activity of the PI3 kinase/Akt/m-TOR pathway. The basic structure of the pathway was reviewed in this article, together with results of the clinical studies targeting mTOR for cancer therapy. This is an exciting area for development and poses many challenges to researchers.

Figures

Figure 1
Figure 1
A diagram of the mTOR pathway.

References

    1. Abraham RT, Wiederrecht GJ (1996) Immunopharmacology of rapamycin. Annu Rev Immunol 14: 483–510
    1. Alexandre J, Raymond E, Depenbrock H (1999) CCI-779, a new rapamycin analog, has antitumour activity at doses inducing only mild cutaneous effects and mucositis: early results of an ongoing phase 1 study. Proceedings of the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics. Washington, DC, November 16–19
    1. Aronica SM, Katzellenbogen B (1991) Progestrogene receptor regulation in uterine cells: stimulation by oestrogen, cyclic adenosine 3,5-monophosphate, and insulin like growth factor I and suppression by antioestrogens and protein kinase inhibitors. Endocrinology 128: 2045–2052
    1. Atkin MB, Hidalgo M, Stadler W, Logan T, Dutcher JP, Hudes G, Park Y, Marshall B, Boni J, Dukart G (2002) A randomises phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Meeting Proceedings American Society of Clinical Oncology: vol 21: Poster Presentation Abst 36
    1. Barbet NC, Schneider U, Helliwell SB, Stansfield I, Tuite MF, Hall MN (1996) TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 7: 25–42
    1. Baselga J, Fumoleau P, Gil M, Colomer H, Roche H, Cortes-Funes H, Burstein H, Kaufman P, Kong S, Moore L (2004) Phase 2, 3-arm study of CCI-779 in combination with Letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. Meeting Proceedings American Society of Clinical Oncology: vol 23: Poster Presentation Abst 544
    1. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL (1994) A mammalian protein target by G1-arresting rapamycin-receptor complex. Nature 369: 756–758
    1. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Simak A, Nakshatri H (2001) Phosphatidyl-insostol-3-kinase/Akt mediated activation of oestrogen alpha: a new model for anti-oestrogen resistance. J Biol Chem 276: 9817–9824
    1. Chan S, Scheulen ME, Johnston S, Mross K, Piccart M, Hess D, Bouxin N, Azali N, for the European CCI-779 Breast Group (2003a) Phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic cancer (MBC) failing prior anthracycline and/or taxane regimens. Meeting Proceedings American Society of Clinical Oncology: vol 22; Oral Presentation Abst 774
    1. Chan SY, Panigrahi AR, Pinder SE, Sharma R, Ellis IO, Robertson JFR, on behalf of the Nottingham Breast Team (2003b) Imunohistochemical study of the PTEN/AKT pathway in early and advanced breast cancer. Program and Proceedings of AACR-NCI-EORTC Internal Conference: Molecular Targets and Cancer Therapeutics Abst B 167, p 159, Boston, MA: Hynes Center
    1. Chan TO, Rittenhouse SE, Tsichlis PN (1999) AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 68: 965–1014
    1. Chao DT, Korsmeyer SJ (1998) BCL-2 family: regulators of cell death. Annu Rev Immunol 16: 395–419
    1. Dancey JE (2000) Rapamycin-sensitive signal-transduction pathway: protein transduction control of cell proliferation. American Society Of Clinical Oncology Educational Book, ASCO 36th annual meeting, New Orleans, LA. pp 68–75
    1. Degrafenried L, Friedrichs W, Fulcher L, Silva J, Roth R, Hidalgo M (2002) The mTOR inhibitor CCI-779 restores Tamoxifen response in breast cancer cells with high Akt activity. 14th NCI-EORTC-AACR symposium on molecular targets and cancer therapeutics. Eur J Cancer 158, abst 528
    1. Dutcher JP, Hudes G, Motzer R, Ko Yj, Smith JW, Zono K, Marhall B, Dukart G, Liou SH (2003) Preliminary report of a phase 1 study of intravenous CCI-779 given in combination with interferon alpa to patients with advanced renal cell carcinoma. Meeting Proceedings American Society of Clinical Oncology: vol 22: Poster Presentation Abst 854
    1. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N (1998) 4E-BP1, a repressor of mRNA translation is phosphorylated and inactivated by the Akt (PKB) signalling pathway. Genes Dev 12: 502–513
    1. Grunwald V, Degrafenried L, Russel D (2002) Inhibitor of mTOR reverses doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62: 6141–6145
    1. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266: 1821–1828
    1. Lane HA (2003) The Rapamycin derivative RAD001 in oncology: what is the endpoint? Program and Proceedings of AACR-NCI-EORTC Internal Conference. Molecular Targets and Cancer Therapeutics November 17–21, Abst Book, pp 259–260, Boston, MA: Hynes Center
    1. Li Z, Wahl MI, Eguinoa A, Stephens LR, Hawkins PT, Witte ON (1997) Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases. Proc Natl Acad Sci USA 94: 13,820–13,825
    1. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G (2003) Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 30(5 Suppl 16): 93–104
    1. Mills GB, Lu Y, Fang X, Wang H, Eder A, Muling M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J (2001) The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis and therapy. Semin Oncol 28: 125–141
    1. Mita MM, Rowinsky EK, Goldston ML, Mita AC, Chu Q, Syed S, Knowles HL, Rivera VM, Bedrosian CL, Tolcher AW (2004) Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of AP23573 an mTOR inhibitor administered IV daily × 5 every other week in patients with refractory or advanced malignancies. Meeting Proceedings American Society of Clinical Oncology: vol 23: Poster Presetnation Abst 3076
    1. Morice WG, Brunn GJ, Wiederrecht G, Siekierka JJ, Abraham RT (1993a) Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 268: 3734–3738
    1. Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ, Abraham RT (1993b) Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J Biol Chem 268(22): 737–745
    1. O'Donnell A, Faivre S, Judson I, Delbado C, Brock C, Lane H, Shand N, Hazell K, Armand JP, Raymond E (2003) A phase 1 study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biological effective dose using toxicity, pharmacokinetic(PK) pharmacodynamic (PD) endpoints in patients with solid tumours. Meeting Proceedings American Society of Clinical Oncology: vol 22: Poster Presentation Abst 803
    1. Paulovich AG, Toczski DP, Hartwell LH (1997) When checkpoints fail. Cell 88: 315–321
    1. Pietras RJ, Arbodela J, Reese DM, Wongvipat N, Pegram M, Ramoss L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ (1995) Her-2 tyrosine kinase pathway targets oestrogen receptor promotes hormone independent growth in human breast cancer cells. Oncogene 10: 2435–2446
    1. Proud CG (1996) P70 s6 kinase: an enigma with variations. Trends Biochem Sci 21: 181–185
    1. Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC (1998) Evidence of insulin-stimulated phosphorylation and activation of mammalian target of rapamycin by a protein kinase B signalling pathway. Proc Natl Acad Sci USA 95: 7772–7777
    1. Sharma R, Pinder SE, Ellis IO, Paish C, Chan SY (2003) 8th Nottingham International Breast Cancer Conference. Abst 55, Eur J Can Suppl 1(4)
    1. Simoncini T, Haferzi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK (2000) Interaction of oestrogen receptor with the regulatory subunit of Phosphatidyl-insostol-3-OH-kinase. Nature 407: 538–541
    1. Smith CL (1998) Cross-talk between peptide growth factor and oestrogen receptor signalling pathways. Biol Reprod 58: 627–632
    1. Workman P (2003) ‘Drugging the PI3K pathway’ Program and Proceedings of AACR-NCI-EORTC Internal Conference. Molecular Targets and Cancer Therapeutic Abst Book, pp 257–258, Boston, MA: Hynes Center
    1. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, Gibbons JJ (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocrine-Relat Cancer 8: 249–258

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅